Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions: 4A10; Drug
Lead sponsor: Allterum Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Efavirenz, Metabolism and Pharmacokinetics Changes
Interventions: Efavirenz, voriconazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Drug Interaction, Food-drug Interaction
Interventions: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Epilepsy, Epilepsy Intractable
Interventions: Green Light Exposure; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol Combination Product, Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more

Conditions: Pharmacokinetics
Interventions: Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: HIV Infections
Interventions: Antiretroviral Regimens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 67
States / cities: Fresno, California • Mill Valley, California • Oakland, California + 32 more

Conditions: Kidney Failure, Acute
Interventions: Pharmacy Dashboard Review and Intervention; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Oral Bacteria Levels in the Mouth
Interventions: Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 22 Years to 58 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: Hallucinogens and psychoactive substances; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: epoetin alfa, placebo; Biological · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 20
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more

Conditions: Healthy Participants
Interventions: BMS-986278, Sildenafil, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: RSV Infection
Interventions: EDP-938, Itraconazole, Rifampin, Quinidine; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Seizure Disorder, Epilepsy
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: OMM treatment arm, Counseling; Procedure · Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Healthy Participants
Interventions: BMS-986256, Famotidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension, Diet, Healthy, Culinary Medicine
Interventions: E-group; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Cancer
Interventions: Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more

Conditions: Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions: Neostigmine, Sugammadex; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Epilepsy, Contraception
Interventions: levonorgestrel IUS; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

Achieving Medication Safety During Acute Kidney Injury

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

Effects of Hallucinogens and Other Drugs on Mood and Performance

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy

Effect of Osteopathic Manipulative Medicine on Parkinson Disease

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

eCulinary Medicine Emphasizing Herbs/Spices to Increase Vegetable Intake

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users